Ci Gaban Samun Nasara! Allurar riga-kafi ta farko ta asali da aka yi niyya ga EBV ta kasar Sin ta shiga gwaje-gwajen asibiti, inda ta kawo sabuwar fata ga marasa lafiya da ke dauke da ciwon hanta

Kwanan nan, Cibiyar Kimanta Magunguna (CDE) ta Hukumar Kayayyakin Lafiya ta Ƙasa ta China ta amince da allurar KSD-101 a hukumance, wadda Kousai ta ƙirƙiro, don shiga gwaje-gwajen asibiti. Wannan ba wai kawai allurar rigakafin ƙwayoyin dendritic na farko ba ne (watsar DC) a China da ta sami amincewar FDA IND, har ma da irinta ta farko a China da Hukumar Abinci da Magunguna ta Amurka ta ba ta suna Fast Track Name (FTD). Wannan muhimmin ci gaba yana nuna sabon zamani a fannin maganin rigakafi na musamman ga ciwace-ciwacen jini da ke da alaƙa da EBV.

3ad190bd90798ca13405007c75db5a4f.png

KSD-101 ita ce allurar rigakafin DC ta farko da Kousai Biotechnology ta ƙirƙiro bisa ga dandalin fasaharta ta "Eco-DC Vax", kuma ita ce samfurin rigakafin DC na farko na asali a China da ya sami amincewar FDA IND. Tsarin aikinta ya haɗa da shirya allurar rigakafin magani ta musamman ta hanyar tattara ƙwayoyin mononuclear na majiyyaci, yana sa su bambanta zuwa ƙwayoyin dendritic a cikin vitro, da kuma ɗora su da takamaiman ƙwayoyin rigakafi masu alaƙa da EBV. Bayan an sake saka allurar a cikin jikin majiyyaci, yana iya kunna daidai kuma ya horar da tsarin garkuwar jiki na majiyyaci don gane da kashe ƙwayoyin ƙari da ke bayyana ƙwayoyin rigakafi na EBV, yayin da yake kafa ƙwaƙwalwar rigakafi mai ɗorewa.

### Bayani Mai Ban Mamaki Game da Asibiti: Shaidar Farko ta Tsaro da Inganci

An riga an tabbatar da yuwuwar KSD-101 a cikin binciken asibiti na baya. A cikin wani bincike na asibiti na Phase I na KSD-101 a matsayin maganin ciwon daji na jini da ke da alaƙa da EBV da ke da alaƙa da sake dawowa da kuma rashin amsawa, ƙimar amsawar da aka yi niyya (ORR) ta kai har zuwa 91.67%, tare da cikakken ƙimar gafartawa (CR) na 83.33% da ƙimar sarrafa cututtuka (DCR) na 100%. Maganin ya kuma nuna amsoshi masu ɗorewa da kuma kyakkyawan bayanin aminci. Wannan bayanai masu ban mamaki suna ba da goyon baya mai ƙarfi ga ƙimar asibiti na KSD-101.

### Me Yasa Za Ka Zabi Kasar China Don Maganin Gaggawa?

Kasar Sin tana ci gaba cikin sauri a fannin binciken asibiti da kuma amfani da fannoni na zamani kamar maganin ƙwayoyin halitta da kuma maganin rigakafi. Sashen Duniya na Asibitin Oncology na Yankin Kudu na Beijing ya sadaukar da kai don haɗa marasa lafiya na duniya da sabbin fasahohin likitanci da kuma damar gwaji na asibiti. Ci gaban KSD-101 cikin sauri a kasar Sin yana nufin cewa marasa lafiya na ƙasashen duniya za su iya samun damar yin amfani da wannan maganin sauyi a baya.

### Tuntube Mu Don Ƙarin Bayani ko Don Tantance Cancantar Cancantar

Idan kai ko wani ƙaunatacce ya kamu da ciwon daji da ke da alaƙa da EBV (kamar lymphoma wanda ba shi da magani na yau da kullun ko CAEBV) kuma kuna da sha'awar maganin KSD-101, muna gayyatarku da gaske da ku tuntuɓi Sashen Duniya na Asibitin Oncology na Yankin Kudu na Beijing. Ƙungiyar likitocinmu ta ƙasa da ƙasa za ta ba da shawarwari na ƙwararru, kimanta bayanan likita, da kuma taimakawa wajen tantance cancantar shiga cikin gwaje-gwajen asibiti masu zuwa.

Da fatan za a tuntube mu nan take ta hanyoyin da ke ƙasa:
Waya: 400-880-3716
WeChat: 17801183037
Email: 100085_010@163.com | myimmnet@163.com (backup)

Mun fahimci cewa kowace dama ta magani batu ne na rayuwa da bege. Sashen Duniya na Asibitin Oncology na Yankin Kudu na Beijing ya kuduri aniyar cike gibin da ke tsakanin marasa lafiya da fasahar likitanci ta zamani tare da ƙwarewar ƙwararru da kulawa mai tausayi. Bari mu yi fatan alheri da kuma aiki tare don shawo kan cutar.

**Sashen Ƙasa da Ƙasa na Asibitin Kula da Cututtukan Cututtuka na Yankin Kudu na Beijing**
Waya: 400-880-3716
WeChat: 17801183037
Email: 100085_010@163.com / myimmnet@163.com

微信图片_20241115181717


Lokacin Saƙo: Maris-17-2026